Sept 2022: The European Commission (EC) has authorized Kite's CAR T-cell therapy Tecartus® (brexucabtagene autoleucel) for the treatment of adult patients 26 years of age and older with relapsed or r...
brexucabtagene-autoleucel
Induction therapy followed by stem cell transplantation has maintained a role in the treatment of mantle cell lymphoma (MCL), according to James Gerson, MD, who added that he continues to recommend tr...
brexucabtagene-autoleucel
October 2021: Brexucabtagene autoleucel (Tecartus, Kite Pharma, Inc.) has been approved by the Food and Drug Administration for adult patients with relapsed or refractory B-cell precursor acute lympho...
brexucabtagene-autoleucel